Durable efficacy and safety with lovotibeglogene autotemcel for sickle cell disease
NCODA Oncology and Hematology Meeting Abstracts · 28.10.2026 · 2 (2)
DOI: 10.67209/wpek1002 ↗Kurz gefasst
Fachartikel in der Zeitschrift NCODA Oncology and Hematology Meeting Abstracts, online erschienen am 28.10.2026. Verfasst von Anish Gupta und 15 weiteren Autor:innen. Die Arbeit nennt 8 Literaturangaben.
Abstract (Originalsprache)
Background
Sickle cell disease (SCD) causes frequent acute pain crises and progressive chronic complications, impacting quality of life (QoL). One-time gene therapy lovotibeglogene autotemcel (lovo-cel), consisting of autologous hematopoietic stem and progenitor cells transduced with the lentiviral vector encoding functional copies of the ß-globin gene (ßA-T87Q), is approved for patients aged ≥12 years.
Objectives
Describe the vaso-occlusive event (VOE)-related efficacy outcomes of lovo-cel in SCD, with 89.8% and 95.9% of participants achieving complete resolution of VOEs and severe VOEs, respectively, at 6–18 months post-infusion. Explain how durable efficacy and quality of life improvements with this one-time gene therapy positively impact patients with SCD and inform the multidisciplinary team’s role in long-term care.
Purpose
We report VOE-related efficacy, durability of response, and QoL outcomes among participants treated with lovo-cel in clinical trials using the current commercial manufacturing process.
Method
Data as of July 2025 were pooled from two prospective trials: HGB-206 (Group C; ≥12 to ≤50 years) and HGB-210 (≥2 to ≤50 years). Follow-up of participants treated with lovo-cel is ongoing in LTF-307. VOE-related endpoints were complete resolution of VOEs (VOE-CR) and severe VOEs (sVOE-CR), assessed during months 6–18 post-lovo-cel infusion among participants with ≥4 VOEs at baseline and ≥18 months of follow-up. Treatment durability (VOEs, HbAT87Q expression, red cell indices, biologic markers of hemolysis) and safety were assessed. Patient-Reported Outcomes Measurement Information System (PROMIS®) QoL outcomes as of July 2024 were evaluated among HGB-206 Group C participants with data available up to 60 months post-lovo-cel.
Results
76 participants (HGB-206, n=43; HGB-210, n=33) initiated mobilization and 63 received lovo-cel; 49/63 were VOE evaluable (median [range] age at enrollment, 23 [12- 38] years; adults [≥18 years], 75.5%; adolescents [≥12 to
Zitieren
APA
Gupta, A., Nelson, K., Kinney, M., Nickel, R., Hsieh, M., Parikh, S., Elliot, H., Pan, L., Mamlouk, K., Rifkin-Zenenberg, S., Thompson, A., Walters, M., Chawla, A., Leonard, A., Tisdale, J., & Kanter, J. (2026). Durable efficacy and safety with lovotibeglogene autotemcel for sickle cell disease. NCODA Oncology and Hematology Meeting Abstracts, 2(2). https://doi.org/10.67209/wpek1002
Vancouver
Gupta A, Nelson K, Kinney M, Nickel R, Hsieh M, Parikh S, et al. Durable efficacy and safety with lovotibeglogene autotemcel for sickle cell disease. NCODA Oncology and Hematology Meeting Abstracts. 2026;2(2). doi:10.67209/wpek1002
BibTeX
@article{Gupta2026,
author = {Gupta, Anish and Nelson, Kristina and Kinney, Melissa and Nickel, Robert and Hsieh, Matt and Parikh, Suhag and Elliot, Heidi and Pan, Lin and Mamlouk, Khalid and Rifkin-Zenenberg, Stacey and Thompson, Alexis and Walters, Mark and Chawla, Anjulika and Leonard, Alexis and Tisdale, John and Kanter, Julie},
title = {Durable efficacy and safety with lovotibeglogene autotemcel for sickle cell disease},
journal = {NCODA Oncology and Hematology Meeting Abstracts},
year = {2026},
volume = {2},
number = {2},
doi = {10.67209/wpek1002}
}
EUVIMED